STOCK TITAN
  1. Home
  2. News
  3. TMDX

Transmedics Group Inc - TMDX STOCK NEWS

Welcome to our dedicated news page for Transmedics Group (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Transmedics Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Transmedics Group's position in the market.

News
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX) granted non-qualified stock options and restricted stock units to 11 employees as an inducement for their employment. The options have a 10-year term with a per share exercise price of $75.11, and the restricted stock units will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
none
-
News
TransMedics to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX) to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference. The chat will take place on November 28, 2023, at 2:30 p.m. Eastern Time. A live and archived webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences
-
News
TransMedics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
TransMedics Group, Inc. reported a net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the same period last year. The company closed the acquisition of Summit Aviation, which contributed to a $2.1 million increase in transplant-related revenue. Gross margin for the quarter was 61%, impacted by transition initiatives and non-transplant related costs. Operating expenses were $69.0 million, driven by research and development charges and acquisition-related costs. The net loss for the quarter was $25.4 million. TransMedics updated its full year 2023 revenue guidance to be in the range of $222 million to $230 million, representing significant growth compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.18%
Tags
earnings
News
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
TransMedics Group, Inc. has granted non-qualified stock options and restricted stock units to 10 employees as a material inducement for their employment. The grants consist of 27,520 shares of common stock and 17,670 restricted stock units. The stock options have an exercise price of $38.05 per share and a 10-year term. Vesting of the options and restricted stock units is subject to the employee's continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
TransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023
Rhea-AI Summary
TransMedics Group, Inc. will release financial results for Q3 2023 on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
-
News
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
TransMedics grants stock options and restricted stock units to employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
none
News
TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Summary
TransMedics to participate in fireside chat at Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences
-
News
TransMedics Completes Acquisition of Summit Aviation
Rhea-AI Summary
TransMedics completes acquisition of Summit Aviation, establishing TransMedics Aviation as the first national provider of air logistics for organ transplantation in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
acquisition
-
News
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
TransMedics Group, Inc. (TMDX) granted non-qualified stock options and restricted stock units to 16 employees as inducement for their employment. The options have a 10-year term and vesting periods, while the restricted stock units vest over four years. The grants were approved by the Compensation Committee and are in accordance with Nasdaq Listing Rule 5635(c)(4) and the TransMedics Group, Inc. Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
none
News
TransMedics Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
earnings
Stock TMDX logo
Transmedics Group Inc

Nasdaq:TMDX

TMDX Rankings

#1565 Ranked by Market Cap
#3404 Ranked by Stock Gains
N/A Ranked by Dividends

TMDX Stock Data

3.02B
31.55M
3.62%
111.73%
18.31%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Andover

About TMDX

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.